<p>ClariVein<sup>®</sup>, mechanochemical endovenous ablation: patient selection and perspective</p>

Abstract

ClariVeinReg, mechanochemical endovenous ablation: patient selection and perspective Amjad Belramman,1 Roshan Bootun,1,2 Sarah Onida,1,3 Alun H Davies,1,3 Tristan RA Lane1,31Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, UK; 2East of England Deanery Vascular Surgery Training Programme, Cambridge, UK; 3Imperial Vascular Unit, Imperial College Healthcare NHS Trust, London, UKCorrespondence: Tristan RA LaneSection of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, 4N12A, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UKEmail tristan.lane@imperial.ac.ukAbstract: The American Venous Forum and the National Institute for Health and Care Excellence recommend endothermal ablation (ETA) techniques as the first line treatment for superficial venous incompetence. However, these techniques require the use of tumescent anaesthesia prior to energy delivery, which may be a source of discomfort for the patient and can prolong procedure time. Recently, nonthermal, nontumescent (NTNTs) techniques such as mechanochemical ablation (MOCA) have been developed to address some of the negative aspects associated with ETA. This article reviews this technique from a patient selection and perspective point view.Keywords: endovenous ablation, varicose veins, venous disease, mechanochemical ablation